Stool vs saliva vs blood microbiome tests
A microbiome test is not one biological measurement, it is sequencing (or culturing) microbes from a particular body site. Stool assays sample the distal colon and rectal lumen, where most consumer gut reports are anchored. Saliva assays sample the oral cavity, a distinct community with partial overlap to the gut via swallowing and the oral–gut axis. Blood assays detect bacterial DNA fragments in plasma; whether that represents translocation from the gut, assay contamination, or transient bacteraemia is contested, and blood is not a standard clinical substitute for stool composition. Skin kits sample yet another habitat, stool does not diagnose skin flora; see Gut–skin axis.
If your question is butyrate production, methane constipation, or FODMAP fermentation, a stool panel is the only consumer matrix that even samples the relevant geography, and even stool does not map the small intestine.
For report routing: Reading your microbiome report.
What not to conclude
| Matrix | Weak conclusion | More accurate framing |
|---|---|---|
| Saliva | Low diversity means colonic dysbiosis | Oral ecology ≠ colon; different pH, oxygen, and diet exposure |
| Saliva | Oral probiotic will fix bloating | Swallowed bacteria may not colonise colon; strain and survival matter |
| Stool | Normal stool rules out SIBO | Stool is downstream; overgrowth can exist proximally with altered distal output |
| Blood bacterial DNA | Proves “leaky gut” dysbiosis | Signal may be low-level, episodic, or technical; not a validated dysbiosis assay |
| Cross-matrix comparison | Oral improved so gut improved | Different pipelines and biology, not paired endpoints |
| Any matrix | One sample = whole-GI portrait | Geography and timing dominate interpretation |
What each matrix measures
| Matrix | Primary biology sampled | Typical consumer output | Main blind spots |
|---|---|---|---|
| Stool | Colonic lumen, fecal transit mix | Bacterial taxa, diversity, some archaea, pathway scores | Small intestine, mucosa-attached communities, rapid proximal fermentation |
| Saliva | Oral mucosa, teeth, gingival crevice | Oral taxa (Streptococcus, Prevotella, Neisseria, etc.) | Colon; esophageal disease unless specialised |
| Blood (plasma DNA) | Circulating bacterial DNA fragments | Often research-only; some wellness panels | Cannot localise source organ reliably on most kits |
| Mucosal biopsy (clinical, not home kit) | Epithelium-adherent layer | Pathology + culture/16S in research | Invasive; not consumer |
The Human Microbiome Project catalogued distinct community profiles by body habitat, skin, oral, stool, and vaginal sites cluster separately (HMP Consortium, 2012). “Healthy microbiome” without a site qualifier is meaningless.
Clinical vs consumer availability by matrix
| Matrix | Consumer direct-to-consumer | Clinical/research use |
|---|---|---|
| Stool | Widest DTC offering (16S, shotgun) | Calprotectin, pathogens, C. diff, FIT, different assays from sequencing |
| Saliva | Oral health and cosmetic kits | Periodontal risk, caries research; some H. pylori antigen tests (not 16S) |
| Blood | Rare; often bundled in disputed wellness panels | Research on sepsis, cancer, and translocation; not guideline-backed for gut health |
| Breath (not microbiome sequencing) | Some home hydrogen devices | Lactulose/glucose breath testing for carbohydrate malabsorption and IMO/SIBO protocols |
Stool sequencing and stool inflammation tests (calprotectin) answer different questions, both can be “stool tests” on a lab menu.
When oral results matter for gut symptoms
Oral–gut links are real but narrower than marketing implies:
- Periodontal disease associates with systemic inflammation markers in epidemiology, causality and intervention benefit for distant symptoms are not established from oral 16S alone.
- Dysphagia, reflux, nausea may originate above the colon; oral or esophageal workup precedes stool interpretation.
- Nitrate-reducing oral bacteria affect salivary nitrite and may interact with host physiology, mostly research context, not consumer report lines.
- PPI use alters upper GI pH and may shift both oral and stool reads (Medications and microbiome).
A high Fusobacterium read in saliva does not tell you whether Faecalibacterium is low in the colon. Treat oral kits as oral reports.
Blood-based claims, evidence limits
Studies detect bacterial DNA in blood from healthy volunteers at low levels, but:
- Concentrations are far below stool biomass, signal-to-noise and contamination control dominate.
- Post-prandial lipoprotein fractions can carry LPS and microbial ligands in metabolic research (Cani et al., 2007), that is biochemistry of metabolic endotoxemia, not a 16S profile of the colon (Metabolic health and endotoxemia).
- Blood “microbiome” panels that imply gut dysbiosis diagnosis outrun validation.
Stool sequencing does not measure serum LPS. Blood metagenomics and stool metagenomics are different assays answering different questions.
How to choose a matrix for your question
| Question | Sensible first matrix | Poor fit |
|---|---|---|
| Colonic butyrate producers, diversity | Stool | Saliva, blood |
| Bloating after FODMAP foods | Stool + dietary trial; breath if malabsorption suspected | Oral kit alone |
| Gum disease, halitosis | Saliva / dental exam | Stool |
| Weight, insulin resistance | Clinical metabolic labs; stool only as research adjunct | Blood bacterial DNA as diagnosis |
| Post-infectious IBS | Clinical history + stool calprotectin if indicated | Any single DTC panel “subtype” |